GV and Takeda have backed a series B round that will fund the Rockefeller University spinout's identification of targets for brain disease treatments.
Cerevance, a US-based brain disease drug developer based on research at Rockefeller University, completed a $45m series B round yesterday featuring Takeda Ventures and GV, on behalf of pharmaceutical firm Takeda and internet and technology group Alphabet respectively.
Foresite Capital, Dementia Discovery Fund (DDF), Lightstone Ventures and entrepreneur Bill Gates also participated in the round, which followed $21.5m in series A funding from Takeda Ventures, Lightstone and DDF when the company launched in 2016.
Cerevance is developing…
